Marksans Pharma
MARKSANS · Pharma > Pharmaceuticals & Drugs · Chairman: Mark Saldanha · MD: Mark Saldanha · Listing date: Jan. 22, 2002 · Employees: 1138 · Mumbai · http://www.marksanspharma.com

Stock Price vs Company Growth
1d
2.3%
1w
0.6%
1m
13.2%
3m
52.6%
6m
46.4%
1y
6.1%
5y
25.7%
10y
18.9%
all
18.1%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 267 2.3%
171
278
Company Overview

Sales
2,951 Cr
Growth: 12.2%
Profit after Tax
418 Cr
Growth: 16.0%
Mid Cap
12,106 Cr
P/E: 28.8x
Industry P/E: 33.7x
Fundamentals

Sales (Cr) ₹ 2,951
Growth 12.2%
EBITDA 20.4%
P/S 4.1x
Dividend 0.4%
P/E 28.8x
Book Value ₹ 66.7
PEG Ratio 2.3x
ROE 15.3%
P/B 3.9x
Shareholding Pattern

Institutions
Promoters
Mark Saldanha
48.25 %
Others
Mukul Mahavir Prasad Agrawal
1.47 %
Increase    Decrease    No change
Company Profile Detailed

The company is a globally-trusted, customer-centric pharmaceutical company with a strong presence in regulated markets. The company specialises in developing and manufacturing & distributing both over-the-counter (OTC) and prescription (Rx) drugs, aligning its offerings with the evolving needs of patients and healthcare providers across the world.
Investors (49)
Followers (8)